Abstracts Archive - Page 1865 of 2607 - ACR Meeting Abstracts

Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon², Kyong-Hee Jung² and Min Jung Son³, ¹Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Inha University Hospital, Incheon, South Korea
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…
Abstract Number: 3171 • 2015 ACR/ARHP Annual Meeting
Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone
Ivana Parody¹, Luis Arias-Urdaneta², Ricardo Garcia Alemany² and Carlos Sesin², ¹Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, ²Vanguard Rheumatology Partners, Miami Beach, FL
Background/Purpose: Patients with RA and other rheumatologic disorders are at increased risk for osteoporotic fractures. Biologic DMARDs are an important treatment option for these patients.…
Abstract Number: 3172 • 2015 ACR/ARHP Annual Meeting
Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia², Eugenio Escolano³, Teresa Velasco¹, Elena García², Esther Vicente-Rabaneda², Alberto Garcia-Vadillo⁴, Rosario Garcia-Vicuña⁴, Isidoro González-Alvaro*² and Santos Castañeda*², ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Radiology Department, H.U La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentatiomn and activation of osteoclasts even before arthritis onset (1,2). The…
Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Lyn March¹, Weiwen Chen², Judy M Simpson³, Fiona Blyth⁴ and Jacqueline Center², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, ³Statistics, University of Sydney School of Public Health, Sydney, Australia, ⁴Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
Abstract Number: 3174 • 2015 ACR/ARHP Annual Meeting
Vitamin D Binding Protein and Tenofovir-Associated Bone Loss Among Individuals with HIV
Evelyn Hsieh^1,2, Liana Fraenkel¹, Weibo Xia³, Yang Han², Michael Yin⁴, Karl Insogna⁵, Ting Zhu² and Taisheng Li², ¹Section of Rheumatology, Yale School of Medicine, New Haven, CT, ²Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China, ³Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China, ⁴Division of Infectious Diseases, Columbia University Medical Center, New York, NY, ⁵Section of Endocrinology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) have been associated with decreases in bone mineral density, and elevations in bone turnover markers (BTM) and…
Abstract Number: 3175 • 2015 ACR/ARHP Annual Meeting
Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass
TM Keaveny¹, DB Crittenden², MA Bolognese³, HK Genant⁴, K Engelke⁵, B Oliveri⁶, JP Brown⁷, BL Langdahl⁸, YC Yang², A Grauer² and C Libanati⁹, ¹UC Berkeley, Berkeley and O.N. Diagnostics, Berkeley, CA, ²Amgen Inc., Thousand Oaks, CA, ³The Bethesda Health Research Center, Bethesda, MD, ⁴UCSF & Synarc Inc., San Francisco, CA, ⁵Synarc Germany, Hamburg, Germany, ⁶Hospital de Clínicas, INIGEM, Buenos Aires, Argentina, ⁷Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a bone-forming agent that inhibits sclerostin. In a phase 2 study (NCT00896532), 12 months of romosozumab increased DXA bone mineral density (BMD)…
Abstract Number: 3176 • 2015 ACR/ARHP Annual Meeting
New Prospects for Interpreting Bony Depressions in Juvenile Idiopathic Arthritis: A Novel MRI Computer-Assisted Technique for Detection of Erosive Progression
Pieter van Dijkhuizen^1,2, Carlotta Covizzi¹, Andrea Schiappacasse³, Michela Moraldo⁴, Matteo Santoro⁵, Francesca Magnaguagno⁶, Gianmichele Magnano⁷, Alberto Martini^1,4 and Clara Malattia^1,4, ¹Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ²UMC Utrecht, Wilhelmina Children’s Hospital, Pediatric rheumatology, Utrecht, Netherlands, ³DIBRIS Università degli studi di Genova, Genova, Italy, ⁴DINOGMI Università degli studi di Genova, Genova, Italy, ⁵Camelot Biomedical Systems, Genova, Italy, ⁶Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, ⁷Istituto G Gaslini, UO Radiologia Pediatrica, Genova, Italy
Background/Purpose: Structural damage is the main disease outcome to be avoided in JIA. The gold standard to assess joint damage in JIA is X-ray, which…
Abstract Number: 3177 • 2015 ACR/ARHP Annual Meeting
Whole-Body MRI: A Valuable Diagnostic Tool for the Assessment of Disease Damage in Juvenile Dermatomyositis
Clara Malattia¹, Agnese Beltramo¹, Isabella Buffoni¹, Annalisa Madeo¹, Francesca Magnaguagno², Stefania Viola¹ and Alberto Martini^1,3, ¹Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ²Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, ³Pediatria, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy
Background/Purpose: Although the prognosis of JDM has significantly improved during the past decade, some patients still experience persistent active disease, which potentially leads to irreversible…
Abstract Number: 3178 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Marina Mesquida³, Alfredo Adan³, M. Victoria Hernández⁴, Olga Maiz Alonso⁵, Antonio Atanes-Sandoval⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Diaz Soriano⁹, Javier Loricera¹, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital La Fe, Valencia, Spain, ³Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Rheumatology, Donostia University Hospital, Donostia, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁷Rheumatology, Hospital Universitario HUVN, Granada, Spain, ⁸Rheumatology, Hospital HSLL, Palma de Mallorca, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to juvenile idiopathic arthritis (JiA).Methods: Multicenter study of uveitis related to JiA…
Abstract Number: 3179 • 2015 ACR/ARHP Annual Meeting
Diagnosing Childhood Small Vessel CNS Vasculitis
Marinka Twilt¹, Maryam Nabavi Nouri², Pascal N. Tyrrell³, Anastasia Dropol¹, Shehla Sheikh⁴, Cynthia Hawkins⁵ and Susanne Benseler^6,7, ¹Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada, ²Neurology, The Hospital for Sick Childern, Toronto, ON, Canada, ³Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada
Background/Purpose: Childhood primary small vessel CNS vasculitis (SVcPACNS) is an increasingly recognized inflammatory brain disease with high morbidity and mortality mandating an elective brain biopsy…
Abstract Number: 3180 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study
Joost Swart¹, Nico Wulffraat², Berent J. Prakken³, Ineke Slaper-Cortenbach⁴ and Caroline Lindemans⁵, ¹PO Box 85090, UMC Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center, Utrecht, Netherlands, ⁴Cell Therapy Facility, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a frequent childhood disease with a prevalence of 1 per 1000 children. The introduction of the biological agents including…
Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Stephanie Shoop¹, Suzanne M. Verstappen², Eileen Baildam³, Alice Chieng⁴, Joyce Davidson^5,6, Helen Foster⁷, Yiannis Ioannou⁸, Flora McErlane⁷, Lucy R Wedderburn⁹, Wendy Thomson¹⁰ and Kimme L. Hyrich¹⁰, ¹ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, ²ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁵The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, ⁶The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, ⁷Royal Victoria Hospital, Newcastle, United Kingdom, ⁸Rayne Institute, University College London, London, UK, London, United Kingdom, ⁹Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, ¹⁰arc Epidemiology Unit, Manchester, United Kingdom
Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
Abstract Number: 3182 • 2015 ACR/ARHP Annual Meeting
High Body Mass Index Negatively Impacts Time to Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from a Multicenter Early Arthritis Cohort Study
Elizabeth Schulman¹, Kathleen Andersen², Meng Zhang³, Susan M. Goodman⁴, Daming Lin⁵, Gilles Boire⁶, Boulos Haraoui⁷, Carol Hitchon⁸, Shahin Jamal⁹, Edward C. Keystone¹⁰, Janet E. Pope¹¹, Diane Tin¹², Carter Thorne¹³, VP Bykerk² and CATCH Investigators, ¹Rheumatology, Hospital for Special Surgey, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁰Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: High BMI has been associated with worse disease severity and lower rates of sustained remission (susREM) in early rheumatoid arthritis (ERA). In this study,…
Abstract Number: 3183 • 2015 ACR/ARHP Annual Meeting
The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis
Jeffrey R. Curtis¹, Lang Chen^1,2, Meredith Kilgore³, Huifeng Yun⁴ and Jeffrey D. Greenberg⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Bimingham, Birmingham, AL, ³Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Corrona, LLC, Southborough, MA
Background/Purpose: Treat to target guidelines recommend achieving a state of remission or low disease activity for rheumatoid arthritis (RA) patients. However, the benefit of lower…
Abstract Number: 3184 • 2015 ACR/ARHP Annual Meeting
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
Sofia Ramiro¹, Robert B.M. Landewé², Désirée van der Heijde¹, Oliver FitzGerald³, Mikkel Østergaard^4,5, Joanne Homik⁶, Ori Elkayam⁷, J Carter Thorne⁸, Margaret Larche⁹, Gianfranco Ferraccioli¹⁰, Marina Backhaus¹¹, Gilles Boire¹², Bernard Combe¹³, Thierry Schaeverbeke¹⁴, Alain Saraux¹⁵, Maxime Dougados¹⁶, Silvano Adami¹⁷, Marcello Govoni¹⁸, Luigi Sinigaglia¹⁹, Alain G. Cantagrel²⁰, Cornelia F. Allaart¹, Cheryl Barnabe²¹, Clifton O. Bingham III²², Paul P. Tak²³, Dirkjan van Schaardenburg²⁴, Hilde Berner Hammer²⁵, Rana Dadashova²⁶, Edna Hutchings²⁶, Joel Paschke²⁶ and Walter Maksymowych²⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ³Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁵Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ⁶Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹⁰Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹²Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ¹³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ¹⁴Rheumatology, Pellegrin University Hospital, Bordeaux, France, ¹⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹⁶Cochin Hospital, Paris Descartes University, Paris, France, ¹⁷University of Verona, Verona, Italy, ¹⁸University of Ferrara, Ferrara, Italy, ¹⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²⁰Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ²¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²²Rheumatology, Johns Hopkins University, Baltimore, MD, ²³Division of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²⁶CaRE Arthritis, Edmonton, AB, Canada, ²⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A Treat-to-Target approach (T2T), treating patients with RA towards a target, either remission or low disease activity (T2T-REM or T2T-LDA), is nowadays recommended. However…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].